Training and Resources
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Neoadjuvant KEYTRUDA® (pembrolizumab) + chemotherapy followed by adjuvant KEYTRUDA monotherapy in patients with triple-negative breast cancer (TNBC)
KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer, at high-risk of recurrence.1
Expert on Demand in Triple-Negative Breast Cancer(TNBC)
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
KEYconversations in early-stage TNBC: Optimising treatment outcomes in early-stage triple-negative breast cancer January 2023 Highlights Report
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
KEYTRUDA® (pembrolizumab) KEYNOTE-522 clinical data presentation
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
KEYNOTE-522: Neoadjuvant KEYTRUDA® (pembrolizumab) plus chemotherapy followed by adjuvant pembrolizumab monotherapy in patients with TNBC
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
MSD Sponsored Satellite Symposium at UKIBCS Conference 2024
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
Managing immune-mediated Adverse Events
Please refer to Summary of Product Characteristics for full list of AEs and management.
KEYTRUDA® (pembrolizumab) + chemotherapy for patients with locally recurrent unresectable or metastatic TNBC
KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥10 and who have not received prior chemotherapy for metastatic disease.1
Please refer to the SmPC for further information before making any prescribing decisions.
More information about KEYTRUDA® (pembrolizumab) in triple-negative breast cancer (TNBC)
References
- KEYTRUDA Summary of Product Characteristics.
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
